G2GBIO, Inc.
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
- Medical device or technology
G2GBIO is developing several long-acting sustained release drugs using its InnoLAMP platform technology. The leading products are 1-month drugs for Alzheimer’s disease, Schizophrenia, and Diabetes/Obesity and 1-week drug for post-operative pain management
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}